| Full Name |
SARS-Associated Coronavirus Spike Mosaic S (N)
|
Abbreviated Name-1 |
SARS-Associated Coronavirus Spike mosaic S(N); |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Liu IJ, et al. Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (SARS)-associated coronavirus in cells derived from throat wash samples of patients with SARS. J. Clin. Microbiol. May 2005; 43(5): 2444-2448.
Ko PC, et al. Emergency medical services utilization during an outbreak of severe acute respiratory syndrome (SARS) and the incidence of SARS-associated coronavirus infection among emergency medical technicians. Acad Emerg Med. Sep 2004; 11(9): 903-911.
Jiang XS, et al. Quantitative analysis of severe acute respiratory syndrome (SARS)-associated coronavirus-infected cells using proteomic approaches: implications for cellular responses to virus infection. Mol. Cell Proteomics. Jul 2005; 4(7): 902-913.
|
|
Description |
GenScript SARS-Associated Coronavirus Spike mosaic S (N) contains the middle section of the Spike protein immunodominant regions, amino acid fragments: (12-53), (90-115), (171-203). SARS-ACSM is purified by proprietary chromatographic techniques. |
Source |
E. coli |
Purity |
Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
Concentration |
1 mg/ml in 25 mM Tris-HCl, 0.4% sarcosyl, 0,25% Triton X-100, 50% glycerol. |
Stability |
Five year frozen, 6 month at +4°C. |
Specificity |
Immunoreactive with sera of SARS-infected individuals. |
Applications |
Antigen in ELISA and Western blots, excellent antigen for detection of SARS with minimal specificity problems. |
Note |
; |
